HGH Fragment 176-191
C-terminal 16-amino acid fragment of growth hormone. Lipolytic activity attributed to this region; lacks GH's IGF-1-mediated growth effects.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Functionally similar to AOD-9604 (a Tyr-modified version). Marketing claim is 'all the fat-loss of GH without IGF-1 elevation' — preclinical evidence partial; rigorous human RCTs minimal.
Functionally redundant with AOD-9604 in stack design. Most consumer claims trace to a small set of preclinical studies. Identity verification poor in grey market.
C-terminal residues 176-191 of HGH.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
HGH Fragment 176-191 — primary mechanism: c-terminal 16-amino acid fragment of growth hormone. lipolytic activity attributed to this region; lacks gh's igf-1-mediated growth effects.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 200-500 µg · daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Research-grey